Palatin Technologies, Inc. (PTN)
USD 0.18
(-56.95%)
USD 0.18
(-56.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -22.49 Million USD | 30.69% |
| 2023 | -32.45 Million USD | 11.29% |
| 2022 | -36.58 Million USD | -9.6% |
| 2021 | -33.38 Million USD | -41.42% |
| 2020 | -23.6 Million USD | -166.04% |
| 2019 | 35.74 Million USD | 37.87% |
| 2018 | 25.92 Million USD | 345.3% |
| 2017 | -10.56 Million USD | 78.54% |
| 2016 | -49.25 Million USD | -184.91% |
| 2015 | -17.28 Million USD | -9.49% |
| 2014 | -15.78 Million USD | -1.3% |
| 2013 | -15.58 Million USD | 17.04% |
| 2012 | -18.78 Million USD | -37.59% |
| 2011 | -13.65 Million USD | -352.94% |
| 2010 | -3.01 Million USD | 58.72% |
| 2009 | -7.3 Million USD | 56.1% |
| 2008 | -16.63 Million USD | 44.19% |
| 2007 | -29.8 Million USD | 2.13% |
| 2006 | -30.45 Million USD | -97.57% |
| 2005 | -15.41 Million USD | 42.4% |
| 2004 | -26.75 Million USD | -27.2% |
| 2003 | -21.03 Million USD | -24.92% |
| 2002 | -16.83 Million USD | -48.42% |
| 2001 | -11.34 Million USD | -32.55% |
| 2000 | -8.55 Million USD | 29.26% |
| 1999 | -12.1 Million USD | -21.0% |
| 1998 | -10 Million USD | -92.31% |
| 1997 | -5.2 Million USD | -19.27% |
| 1996 | -4.36 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.1 Million USD | 43.53% |
| 2024 Q4 | -8.34 Million USD | 9.44% |
| 2024 Q3 | -9.19 Million USD | -38.24% |
| 2024 Q2 | -6.65 Million USD | -8.86% |
| 2023 FY | -32.45 Million USD | 11.29% |
| 2023 Q3 | -7.3 Million USD | -10.39% |
| 2023 Q2 | -6.61 Million USD | 24.43% |
| 2023 Q1 | -8.75 Million USD | 33.19% |
| 2023 Q4 | -10.81 Million USD | -48.17% |
| 2022 FY | -36.58 Million USD | -9.6% |
| 2022 Q1 | -7.21 Million USD | 47.34% |
| 2022 Q2 | -8.45 Million USD | -17.12% |
| 2022 Q3 | -7.82 Million USD | 7.46% |
| 2022 Q4 | -13.1 Million USD | -67.52% |
| 2021 Q1 | -3.94 Million USD | 46.61% |
| 2021 FY | -33.38 Million USD | -41.42% |
| 2021 Q2 | -9.24 Million USD | -134.44% |
| 2021 Q3 | -6.48 Million USD | 29.88% |
| 2021 Q4 | -13.7 Million USD | -111.26% |
| 2020 Q3 | -5.71 Million USD | -1.28% |
| 2020 Q1 | -4.86 Million USD | -109.32% |
| 2020 Q2 | -5.64 Million USD | -16.01% |
| 2020 Q4 | -7.38 Million USD | -29.34% |
| 2020 FY | -23.6 Million USD | -166.04% |
| 2019 Q2 | -5.05 Million USD | 10.28% |
| 2019 Q1 | -5.62 Million USD | -145.88% |
| 2019 Q3 | -5.76 Million USD | -14.11% |
| 2019 Q4 | 52.18 Million USD | 1005.57% |
| 2019 FY | 35.74 Million USD | 37.87% |
| 2018 Q2 | 2.94 Million USD | -73.82% |
| 2018 Q1 | 11.23 Million USD | -21.55% |
| 2018 FY | 25.92 Million USD | 345.3% |
| 2018 Q3 | -517.44 Thousand USD | -117.59% |
| 2018 Q4 | 12.26 Million USD | 2471.1% |
| 2017 Q3 | -3.01 Million USD | 68.09% |
| 2017 Q4 | 14.31 Million USD | 575.36% |
| 2017 FY | -10.56 Million USD | 78.54% |
| 2017 Q2 | -9.44 Million USD | 24.08% |
| 2017 Q1 | -12.43 Million USD | 2.38% |
| 2016 Q3 | -12.08 Million USD | 4.3% |
| 2016 Q4 | -12.73 Million USD | -5.4% |
| 2016 FY | -49.25 Million USD | -184.91% |
| 2016 Q2 | -12.62 Million USD | -7.04% |
| 2016 Q1 | -11.79 Million USD | -0.15% |
| 2015 Q4 | -11.78 Million USD | -35.06% |
| 2015 Q2 | 2.32 Million USD | 159.84% |
| 2015 FY | -17.28 Million USD | -9.49% |
| 2015 Q3 | -8.72 Million USD | -475.54% |
| 2015 Q1 | 893.88 Thousand USD | 120.69% |
| 2014 Q3 | -3.36 Million USD | 6.83% |
| 2014 Q2 | -3.61 Million USD | 19.64% |
| 2014 Q1 | -4.49 Million USD | 4.82% |
| 2014 FY | -15.78 Million USD | -1.3% |
| 2014 Q4 | -4.32 Million USD | -28.45% |
| 2013 Q3 | -4.02 Million USD | -16.94% |
| 2013 Q4 | -4.72 Million USD | -17.31% |
| 2013 FY | -15.58 Million USD | 17.04% |
| 2013 Q1 | -3.4 Million USD | 40.25% |
| 2013 Q2 | -3.44 Million USD | -1.18% |
| 2012 FY | -18.78 Million USD | -37.59% |
| 2012 Q4 | -5.69 Million USD | 5.57% |
| 2012 Q3 | -6.02 Million USD | -62.82% |
| 2012 Q2 | -3.7 Million USD | -9.94% |
| 2012 Q1 | -3.36 Million USD | 26.6% |
| 2011 FY | -13.65 Million USD | -352.94% |
| 2011 Q4 | -4.58 Million USD | -75.28% |
| 2011 Q3 | -2.61 Million USD | -42.85% |
| 2011 Q2 | -1.83 Million USD | 60.34% |
| 2011 Q1 | -4.61 Million USD | -8.57% |
| 2010 Q4 | -4.25 Million USD | -109.01% |
| 2010 Q2 | 3.43 Million USD | 2238.13% |
| 2010 Q1 | -160.67 Thousand USD | 31.2% |
| 2010 FY | -3.01 Million USD | 58.72% |
| 2010 Q3 | -2.03 Million USD | -159.24% |
| 2009 FY | -7.3 Million USD | 56.1% |
| 2009 Q2 | -2.77 Million USD | 36.26% |
| 2009 Q3 | 72.21 Thousand USD | 102.6% |
| 2009 Q4 | -233.52 Thousand USD | -423.4% |
| 2009 Q1 | -4.36 Million USD | 18.27% |
| 2008 FY | -16.63 Million USD | 44.19% |
| 2008 Q1 | -625.15 Thousand USD | 90.39% |
| 2008 Q2 | -5.37 Million USD | -760.2% |
| 2008 Q3 | -5.29 Million USD | 1.55% |
| 2008 Q4 | -5.33 Million USD | -0.78% |
| 2007 Q1 | -8.75 Million USD | -6.42% |
| 2007 FY | -29.8 Million USD | 2.13% |
| 2007 Q3 | -7.06 Million USD | 5.63% |
| 2007 Q2 | -7.48 Million USD | 14.51% |
| 2007 Q4 | -6.5 Million USD | 7.82% |
| 2006 FY | -30.45 Million USD | -97.57% |
| 2006 Q2 | -8.32 Million USD | -35.14% |
| 2006 Q4 | -8.22 Million USD | -6.13% |
| 2006 Q3 | -7.74 Million USD | 6.88% |
| 2006 Q1 | -6.15 Million USD | -19.9% |
| 2005 Q1 | -3.14 Million USD | 54.58% |
| 2005 Q2 | -3.02 Million USD | 3.83% |
| 2005 Q3 | -4.09 Million USD | -35.27% |
| 2005 FY | -15.41 Million USD | 42.4% |
| 2005 Q4 | -5.13 Million USD | -25.33% |
| 2004 FY | -26.75 Million USD | -27.2% |
| 2004 Q2 | -4.91 Million USD | 27.77% |
| 2004 Q3 | -8.11 Million USD | -65.14% |
| 2004 Q4 | -6.93 Million USD | 14.51% |
| 2004 Q1 | -6.8 Million USD | -3.74% |
| 2003 Q2 | -4.64 Million USD | -11.98% |
| 2003 Q4 | -6.55 Million USD | -15.12% |
| 2003 Q3 | -5.69 Million USD | -22.69% |
| 2003 Q1 | -4.14 Million USD | 18.64% |
| 2003 FY | -21.03 Million USD | -24.92% |
| 2002 Q3 | -4.56 Million USD | -13.66% |
| 2002 FY | -16.83 Million USD | -48.42% |
| 2002 Q1 | -2.74 Million USD | 25.67% |
| 2002 Q2 | -4.01 Million USD | -45.98% |
| 2002 Q4 | -5.09 Million USD | -11.66% |
| 2001 FY | -11.34 Million USD | -32.55% |
| 2001 Q4 | -3.69 Million USD | -27.03% |
| 2001 Q3 | -2.91 Million USD | -19.91% |
| 2001 Q2 | -2.42 Million USD | -5.25% |
| 2001 Q1 | -2.3 Million USD | -1.4% |
| 2000 Q4 | -2.27 Million USD | -18.85% |
| 2000 Q2 | -2.9 Million USD | -107.14% |
| 2000 Q3 | -1.91 Million USD | 33.99% |
| 2000 Q1 | -1.4 Million USD | 64.1% |
| 2000 FY | -8.55 Million USD | 29.26% |
| 1999 Q4 | -3.9 Million USD | -30.0% |
| 1999 Q1 | -2.9 Million USD | 12.12% |
| 1999 Q2 | -2.1 Million USD | 27.59% |
| 1999 FY | -12.1 Million USD | -21.0% |
| 1999 Q3 | -3 Million USD | -42.86% |
| 1998 Q1 | -2 Million USD | -8.11% |
| 1998 FY | -10 Million USD | -92.31% |
| 1998 Q4 | -3.3 Million USD | -43.48% |
| 1998 Q2 | -2.2 Million USD | -10.0% |
| 1998 Q3 | -2.3 Million USD | -4.55% |
| 1997 Q4 | -1.85 Million USD | -37.04% |
| 1997 Q1 | -1.31 Million USD | 0.0% |
| 1997 FY | -5.2 Million USD | -19.27% |
| 1997 Q3 | -1.35 Million USD | -14.41% |
| 1997 Q2 | -1.18 Million USD | 9.92% |
| 1996 FY | -4.36 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 29.515% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -136.353% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 44.984% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 56.672% |
| Azitra, Inc. | -7.61 Million USD | -195.364% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -174.51% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -227.823% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 22.406% |
| CEL-SCI Corporation | -31.47 Million USD | 28.529% |
| iBio, Inc. | -16.63 Million USD | -35.242% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 9.044% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -11.464% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 5.343% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -60.105% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -349.653% |
| NanoViricides, Inc. | -8.51 Million USD | -164.16% |
| Oragenics, Inc. | -20.9 Million USD | -7.612% |
| BiomX Inc. | -27.68 Million USD | 18.743% |
| BiomX Inc. | -27.68 Million USD | 18.743% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 315.068% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 46.479% |
| Theriva Biologics, Inc. | -21.43 Million USD | -4.97% |